Multiple Myeloma
Conditions
Brief summary
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Interventions
DRUGCevostamab
Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
DRUGTocilizumab
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
DRUGPomalidomide
Pomalidomide will be administered orally (PO) on a 28-day cycle.
DRUGDaratumumab
Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
DRUGDexamethasone
Arm A: Dexamethasone will be administered as a premedication. Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product.
Sponsors
Genentech, Inc.
Hoffmann-La Roche
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Agreement to provide bone marrow biopsy and aspirate samples * Resolution of adverse events from prior anti-cancer therapy to Grade \<=1 * Measurable disease * For women of childbearing potential: agreement to remain abstinent or use contraception, during the treatment period (including treatment interruptions) and for at least 5 months after the last dose of cevostamab and at least 3 months after the last dose of tocilizumab was administered * For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, during the treatment period, and for at least 2 months after the last dose of tocilizumab was administered to avoid exposing the embryo and sexual partner Additional Arm A-Specific Inclusion Criteria * Diagnosis of R/R MM for which no established therapy for MM is appropriate and available, or intolerance to those established therapies Additional Arm B-Specific Inclusion Criteria * For Cohort B1S: Participants with R/R MM who have received at least two prior lines of treatment * For Cohort B2S and additional cohorts: Participants with R/R MM who have received at least 1 prior line of treatment * Agreement to comply with all requirements of the pomalidomide pregnancy prevention program * For women of childbearing potential: agreement to remain abstinent or use two reliable methods of contraception starting at least 4 weeks prior to, during the treatment period, and for at least 4 weeks after the last dose of pomalidomide was administered * For men: agreement to remain abstinent or use a condom during the treatment period and for at least 4 weeks after the last dose of pomalidomide, (even if he has undergone a successful vasectomy) and agreement to refrain from donating sperm and blood during this same period Additional Arm C-Specific Inclusion Criteria * For Cohort C1S: Participants with R/R MM who have received at least two prior lines of treatment * For Cohort C2S and additional cohorts: Participants with R/R MM who have received at least 1 prior line of therapy * For women of childbearing potential: agreement to remain abstinent or use contraceptive methods during the treatment period and for at least 102 days after the last dose of daratumumab was administered * For men: agreement to remain abstinent or use a condom during the treatment period and for at least 102 days after the last dose of daratumumab was administered to avoid exposing the embryo, and agreement to refrain from donating sperm during this same period
Exclusion criteria
* Prior treatment with cevostamab or another agent targeting FcRH5 * Inability to comply with protocol-mandated hospitalization and activities restrictions * Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the last dose of cevostamab or within 3 months after the last dose of tocilizumab (if applicable). * Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drugconjugate as anti-cancer therapy within 4 weeks before first study treatment, except for the use of non-myeloma therapy * Prior treatment with systemic immunotherapeutic agents, including, but not limited to, cytokine therapy and anti-CTLA4, anti-PD-1, and antiPD-L1 therapeutic antibodies within 12 weeks or 5 half-lives of the drug, whichever is shorter, before first study treatment * Prior treatment with chimeric antigen receptor T (CAR T)-cell therapy within 12 weeks before first study treatment * Treatment with radiotherapy within 4 weeks (systemic radiation) or 14 days (focal radiation) prior to first study treatment * Treatment with any chemotherapeutic agent or other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment * Autologous SCT within 100 days prior to first study treatment * Prior allogeneic stem cell transplant(ation) (SCT) * Circulating plasma cell count exceeding 500/micro L or 5% of the peripheral blood white cells * Prior solid organ transplantation * History of autoimmune disease * History of confirmed progressive multifocal leukoencephalopathy * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy * Known history of amyloidosis * Lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare * History of other malignancy within 2 years prior to screening * Known treatment-related, immune-mediated adverse events associated with prior checkpoint inhibitors * Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease, or CNS involvement by MM * Significant cardiovascular disease * Symptomatic active pulmonary disease or requiring supplemental oxygen * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection * Known or suspected chronic active Epstein-Barr virus (EBV) infection * Recent major surgery within 4 weeks prior to first study treatment * Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection * Acute or chronic hepatitis C virus (HCV) infection * Known history of Grade \>= 3 CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) with prior bispecific therapies * Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) * Active symptomatic coronavirus disease 2019 (COVID-19) infection at study enrollment or requiring treatment with intravenous (IV) antiviral where the last dose of IV antiviral treatment was given within 14 days prior to first study treatment. Patients with active COVID-19 infection must have clinical recovery and two negative antigen tests at least 24 hours apart prior to first study treatment * Positive and quantifiable EBV polymerase chain reaction (PCR) or Cytomegalovirus (CMV) PCR prior to first study treatment * Known history of HIV seropositivity * Administration of a live, attenuated vaccine within 4 weeks before first study treatment or anticipation that such a live attenuated vaccine will be required during the study * Treatment with systemic immunosuppressive medications, with the exception of corticosteroid treatment \<=10 mg/day prednisone or equivalent, within 2 weeks prior to first study treatment * History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment Additional Arm B-Specific
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recommended Phase II Dose (RP2D) | Baseline up to approximately 4 years |
| Percentage of Participants with Adverse Events | Baseline up to approximately 4 years |
| Percentage of Dose Interruptions | Baseline up to approximately 4 years |
| Percentage of Dose Reductions | Baseline up to approximately 4 years |
| Percentage of Dose Intensity | Baseline up to approximately 4 years |
| Percentage of Treatment Discontinuation | Baseline up to approximately 4 years |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | Baseline up to approximately 4 years |
| Complete Response/Stringent Complete Response (CR/sCR) Rate | Baseline up to approximately 4 years |
| Rate of Very Good Partial Response (VGPR) or Better | Baseline up to approximately 4 years |
| Progression-free Survival (PFS) | Start of study treatment to first date of disease progression or death from any cause, whichever occurs first (up to approximately 4 years) |
| Duration of Response (DOR) | From first partial response (PR) or better until the first date of disease progression or death from any cause, whichever occurs first (up to approximately 4 years) |
| Time to First Response (for Participants who Achieve a Response of Partial Response (PR) or Better) | Baseline up to approximately 4 years |
| Time to Best Response (for Participants who Achieve a Response of PR or Better) | Baseline up to approximately 4 years |
| Minimal Residual Disease (MRD) Negativity | Baseline up to approximately 4 years |
| Overall Survival (OS) | Baseline up until death from any cause (up to approximately 4 years) |
| Serum Concentration of Cevostamab at Specified Timepoints | Cevostamab Pre-Phase (CPP) Day (D) 1 up to approximately 3 years |
| Total Exposure (Area Under the Concentration-time Curve [AUC]) of Cevostamab | CPP D1 up to approximately 4 years |
| Maximum Observed Serum Concentration (Cmax) of Cevostamab | CPP D1 up to approximately 4 years |
| Minimum Observed Serum Concentration (Cmin) of Cevostamab | CPP D1 up to approximately 4 years |
| Clearance of Cevostamab | CPP D1 up to approximately 4 years |
| Volume of Distribution at Steady State of Cevostamab | CPP D1 up to approximately 4 years |
| Number of Anti-drug Antibody (ADAs) Against Cevostamab at Baseline | Baseline |
| Percentage of Participants with ADAs Against Cevostamab During the Study | Up to approximately 4 years |
| Serum Concentration of Pomalidomide | From Cycle 1 Day 1 through Cycle 6 Day 15. Each cycle=28 days |
| Serum Concentration of Daratumumab | From C1D1 until disease progression or unexpected toxicity. Cycles 1-8 are 21 days and Cycle 9 onward are 28 days. |
Countries
Australia, Canada, Czechia, Denmark, France, Israel, Italy, Japan, Poland, South Korea, Spain, United Kingdom, United States
Contacts
STUDY_DIRECTORClinical Trials
Genentech, Inc.
Outcome results
None listed